Individual fecal α1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis

Hepato-Gastroenterology

Volumn 46, Issue 28, 1999, Pages 2309-2314

  Becker, Klaus ^a,b   Berger, Melanie ^a   Niederau, Christoph ^a   Frieling, Thomas ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Florence Nightingale Krankenhaus   (Germany)

Author keywords

1 antitrypsin; Crohn's disease; Disease activity; Intestinal protein loss; Ulcerative colitis

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FECES LEVEL; FEMALE; FOLLOW UP; HUMAN; MALE; NEPHELOMETRY; PATIENT MONITORING; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0032830280     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Crossley JR, Elliott RB: Simple method for diagnosing protein-losing enteropathies. Br Med J 1977; 1:428-429.
2. Bernier JJ, Florent C, Desmazures C, Aymes C, L'Hirondel C: Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; ii:763-764.
3. Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ: Intestinal clearance of α1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterol 1981, 81:777-780.
4. Karbach U, Ewe K, Bodenstein H: Alpha1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut 1983; 24:718-723.
5. Meyers S, Wolke A, Field SP, Feuer EJ, Johnson JW, Janowitz HD: Fecal α1-antitrypsin measurement: an indicator of Crohn's disease activity. Gastroenterol 1985; 89:13-18.
6. Strygler B, Nicer MJ, Santangelo WC, Porter JL, Fordtran JS: α1-Antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990; 99:1380-1387.
7. Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH: Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995; 55:35-45.
8. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994; 35:231-235.
9. Moran A, Jones A, Asquith P: Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995; 30:356-360.
10. Karbach U, Ewe K, Dehos H: Antiinflammatory treatment and intestinal α1-antitrypsin clearance in active Crohn's disease. Dig Dis Sci 1985; 30:229-235.
11. Meyers S, Lichtiger S, Feuer EJ, Lahman EA, Janowitz HD: Fecal α1-antitrypsin as a measure of Crohn's disease activity. J Clin Gastroenterol 1988; 10:491-497.
12. Hundegger K, Stufler M, Karbach U: Enteric protein loss as a marker of intestinal inflammatory activity in Crohn's disease: comparability of enteric clearance and stool concentration of alpha-1-antitrypsin? Z Gastroenterol 1992; 30:722-728.
13. Florent C, L'Hirondel C, Desmazures C, Giraudeaux V, Bernier JJ: Ivaluation de l'évolutivité de la maladie de Crohn et de la rectocolite hémorragique par la mesure de la clairance ficale de l' α1-antitrypsine. Gastroenterol Clin Biol 1981; 5:193-197.
14. Griffiths AM, Drobnies A, Soldin SJ, Hamilton JR: Enteric protein loss measured by fecal α1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents. J Pediatr Gastroenterol Nutr 1986; 5:907-911.
15. Fischbach W, Becker W, Mössner J, Koch W, Reiners C: Faecal alpha-1-antitrypsin and excretion of 111Indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987; 28:386-393.
16. Arndt B, Schürmann G, Betzler M, Herfarth C, Schmidt-Gayk H: Assessment of Crohn's disease activity and α1-antitrypsin in faeces. Lancet 1992; 340:1037.
17. Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG: Evaluation of intestinal clearance and faecal excretion of α1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992; 30:197-202.
18. Miura S, Yoshioka M, Tanaka S, Serizawa H, Tashiro H, Asakura H, et al: Faecal clearance of α1-antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991; 6:49-52.
19. Stufler MHM, Ewe K, Gierlasinski B, Prón H, Zutt M: Elevated serum α1-antitrypsin does not cause increased fecal α1-AT excretion in patients with normal bowel. German J Gastroenterol 1991; 29:11-15.
20. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H: Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437-1439.
21. Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterol 1976; 70:439-444.
22. Rachmilewitz D: Coated mesalazine (5-aminosalicyl acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 1989; 298:82-86.
23. Boege F, Deubel M, Schwarte B, Fischbach W: A simple and time-saving method for the immunenephelometric determination of fecal alpha1-antitrypsine. Lab med 1989; 13:254-258.
24. Becker K, Lindner C, Frieling T, Niederau C, Reinauer H, Häussinger D: Intestinal protein leakage in the acquired immunodeficiency syndrome. Journal of Clinical Gastroenterol 1997; 25:426-428.
25. Crama-Bohbouth G, Pepa AS, Biemond I, Verspaget HW, Blok D, Arndt JW, et al: Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease. Gut 1989; 30:1236-1240.
26. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterol 1990; 98:811-818.
27. Landi B, N'Guyen Anh T, Cortot J, Sonic JC, Rene E, Gendre J-P, et al: Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterol 1992; 102:1647-1653.
28. Boirivant M, Pallone F, Ciaco A, Leoni M, Fais S, Torsoli A: Usefulness of fecal α1-antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis Sci 1991; 36:347-352.
29. Boerr LAR, Sambuelli AM, Sngai E, Negreira S, Gonçalvez S, Gil A, et al: Alpha1-antitrypsin clearance predicts clinical relapses in quiescent Crohn's disease. Gastroenterol 1996; 110:A868.